• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

[UKGTS trial] Latanoprost helps preserve visual field in open-angle glaucoma

byMelissa McCoyandXiaozhou Liu
December 19, 2014
in Chronic Disease, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with open-angle glaucoma treated with latanoprost experienced significantly longer preservation of visual acuity and greater reduction of intraocular pressure than did patients treated with placebo eye drops.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Open-angle glaucoma is the leading cause of irreversible blindness worldwide and is typically treated with intraocular-pressure-lowering drugs like latanoprost. This study aimed to assess the effect of latanoprost on the preservation of visual field in patients with open-angle glaucoma. Patients with open-angle glaucoma were randomly allocated to receive either latanoprost or placebo eye drops. Time to visual field deterioration was measured as the primary outcome within the next 24 months. Visual field preservation was significantly longer in the latanoprost group as compared to the placebo. The randomized controlled study design allows the establishment of causation between intervention and outcome, as well as minimizes provider and observation biases. Relatively high loss to follow-up may moderately limit the power of this study.

This study was funded by Pfizer and the UK National Institute for Health Research Biomedical Research Centre.

Click to read the study, published today in The Lancet

Relevant Reading: An evidence-based review of prognostic factors for glaucomatous visual field progression

RELATED REPORTS

Community-based adult vision screening program increases access to eye care

Preclinical detectable phase for open-angle glaucoma estimated at 10 years

Very low-fat diet may be associated with increased glaucoma risk

In-Depth [randomized controlled trial]: This study aimed to assess the effect of latanoprost 0.005% eye drops on the preservation of visual field in patients with open-angle glaucoma. Patients with new-onset open-angle glaucoma were randomly allocated (1:1) to either receive latanoprost 0.005% or latanoprost vehicle eye drops (placebo) in both eyes once a day. During the period from December 2006 to March 2010, the study enrolled 516 patients and the final data analyses included 461 patients.

The primary endpoint was time to visual field deterioration. Visual field testing and intraocular pressure measurements were completed at 18 months and 24 months. The latanoprost group showed significantly longer visual field preservation than the placebo group (adjusted hazard ratio, 0.44; 95% confidence interval, 0.28-0.69; p=0.0003). At 24 months, the latanoprost group also demonstrated a greater lowering of intraocular pressure in 231 patients of 3.8mmHg (standard deviation, SD, 4.0) when compared to 0.9 mmHg (SD 3.8) in 230 placebo patients.

More from this author: 40-year trends of net cancer survival reveal improved outcomes, START intervention for dementia caregivers linked to reduction of depression symptoms, Mechanical CPR provides no benefit over manual CPR [PARAMEDIC trial], Group B streptococcus infections on the rise despite prevention guidelines, Transplanted stem cells help restore sight in age-related macular degeneration

Image: P

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: glaucoma
Previous Post

Nanoparticle delivery of proteasomes may improve Alzheimer’s therapy [Pre Clinical]

Next Post

Cell-loaded scaffold implant may improve cell therapy [PreClinical]

RelatedReports

Roux-en-Y gastric bypass may slow progression of diabetic retinopathy
Ophthalmology

Community-based adult vision screening program increases access to eye care

January 27, 2023
Roux-en-Y gastric bypass may slow progression of diabetic retinopathy
2 Minute Medicine

Preclinical detectable phase for open-angle glaucoma estimated at 10 years

December 5, 2022
FDA-approved weight loss medications associated with weight loss at one year
Ophthalmology

Very low-fat diet may be associated with increased glaucoma risk

November 22, 2022
Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren
Chronic Disease

Long-term variability in intraocular pressures associated with glaucoma disease progression

November 8, 2022
Next Post
Donor and recipient regulatory T-cells may promote transplant tolerance in mice

Cell-loaded scaffold implant may improve cell therapy [PreClinical]

Long-term active surveillance may be safe in low-risk prostate cancer

Long-term active surveillance may be safe in low-risk prostate cancer

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind July 7, 2025
  • Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
  • Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.